Global Antidepressant Drugs Market Forecast 2018-2024: Increase in the Prevalence of Depression and Growing Awareness Levels About the State of the Disease Will Drive the Market - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Oct 11, 2018--The “Global Antidepressant Drugs Market Forecast up to 2018-2024” report has been added to ResearchAndMarkets.com’s offering.
Depression is a serious mental illness affecting more than 350 million people globally. This is also known as major depression disorder or unipolar depression. According to a report by the Psychiatric Association, nearly 14.8 million adults in the US are suffering from depression. An ageing population and the increasing prevalence of depression are the primary factors driving the global antidepressant drugs market growth. Supportive initiatives from the government and other organizations and increasing clinical trials will provide an opportunity for the market growth in the future.
At the global level, over 300 million people are estimated to suffer from depression, which is equivalent to 4.4% of the world’s total population. Only less than 10% of the affected people are treated although there is the availability of branded and effective treatments for depression. The challenges for effective care include lack of capitals, unavailability of qualified health-care providers, and public stigma associated with mental disorders. Along with these, imprecise assessment of the condition is also a challenge faced globally.
The regions covered in the report are North America, Europe, Asia Pacific, and Rest of the World (ROW). North America accounts for the largest share of the antidepressant drugs market, followed by Europe, Asia Pacific, and Rest of the World. North America alone occupies more than 30% of the market, with a significant contribution from the US to market growth.
Based on the drug class, the market is segmented into selective serotonin reuptake inhibitors (SSRIs), norepinephrine-dopamine reuptake inhibitors (NDRI), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), and others. SSRIs are the most attractive drug in the market, owing to the highly effective treatment of depression and anxiety.
Key Players in this market areNovartis AG Allergan Inc Elli Lilly and Company AstraZeneca plc GSK Otsuka Holdings Co., Ltd Johnson & Johnson
The other prominent players includePfizer Shionogi & Co. Ltd Abbott Laboratories Takeda Pharmaceutical Co., Ltd. H. Lundbeck A/S
DriversIncreasing aging population Increasing prevalence of Depression
OpportunitiesGovernment Initiatives Exhaustive Pipeline and Increasing Clinical Trials
RestraintsComplex drug development process Adverse effects of antidepressant drugs
Key Topics Covered:
1 Industry Outlook
2 Report Outline
3 Market Snapshot
4 Market Outline
5 Market Characteristics
6 Drug Class: Market Size and Analysis
7 Regions: Market Size and Analysis
8 Competitive Landscape
9 Vendor Profiles
10 Companies to Watch for
For more information about this report visit https://www.researchandmarkets.com/research/vjw3lj/global?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20181011005555/en/
Laura Wood, Senior Press Manager
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Mental Disorders Drugs
KEYWORD: UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: HEALTH CLINICAL TRIALS MENTAL HEALTH PHARMACEUTICAL MANAGED CARE
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 10/11/2018 10:31 AM/DISC: 10/11/2018 10:31 AM